期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 205, 期 12, 页码 2781-2789出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20081588
关键词
-
资金
- Canadian Institutes of Health Research (CIHR)
- Jack Brown and Family Alzheimer's Research Foundation
- Michael Smith Foundation for Health Research
- Arthur and June Willms Fellowships
- China Scholarship Council award
- MSFHR Senior Graduate Studentship
- CIHR Doctoral Research Award
Neuritic plaques in the brains are one of the pathological hallmarks of Alzheimer's disease (AD). Amyloid beta-protein (A beta), the central component of neuritic plaques, is derived from beta-amyloid precursor protein (APP) after beta- and gamma- secretase cleavage. The molecular mechanism underlying the pathogenesis of AD is not yet well defined, and there has been no effective treatment for AD. Valproic acid (VPA) is one of the most widely used anticonvulsant and mood-stabilizing agents for treating epilepsy and bipolar disorder. We found that VPA decreased A beta production by inhibiting GSK-3 beta-mediated gamma-secretase cleavage of APP both in vitro and in vivo. VPA treatment significantly reduced neuritic plaque formation and improved memory deficits in transgenic AD model mice. We also found that early application of VPA was important for alleviating memory deficits of AD model mice. Our study suggests that VPA may be beneficial in the prevention and treatment of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据